Screener
Alnylam Pharmaceuticals ALNY Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 302,176 | 281,892 |
| Total current assets | 4,620,172 | 4,050,662 |
| Property, plant and equipment, net | 554,143 | 513,147 |
| Operating lease right-of-use assets | 183,359 | 194,916 |
| Deferred tax assets | 113,792 | 125,975 |
| Restricted investments | 22,171 | 22,170 |
| Other assets | 65,132 | 59,461 |
| Total assets | $5,558,769 | $4,966,331 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's operating lease ROU assets?
- Alnylam Pharmaceuticals (ALNY) reported operating lease ROU assets of $183.36M in Q2 2026.
- How has Alnylam Pharmaceuticals's operating lease ROU assets changed year-over-year?
- Alnylam Pharmaceuticals's operating lease ROU assets decreased by 4.7% year-over-year, from $192.4M to $183.36M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating lease ROU assets?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's operating lease ROU assets has grown at a -4.2% compound annual growth rate (CAGR), from $241.49M to $194.92M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Alnylam Pharmaceuticals's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude